老虎证券
Invest
Pricing
Rewards
Support
Learn
About
Quotes
TigerAI
登录
立即注册
Toggle
澳股
详情
本页面由Tiger Trade Technology Pte. Ltd.提供服务
NEUREN PHARMACEUTICALS LTD
13.510
+0.200
1.50%
成交量:
60.20万
成交额:
805.66万
市值:
17.11亿
市盈率:
11.77
高:
13.560
开:
13.320
低:
13.040
收:
13.310
52周最高:
22.985
52周最低:
8.610
股本:
1.27亿
流通股本:
1.08亿
量比:
0.69
换手率:
0.56%
股息:
- -
股息率:
- -
每股收益(TTM):
1.148
每股收益(LYR):
1.086
净资产收益率:
54.96%
总资产收益率:
41.13%
市净率:
5.29
市盈率(LYR):
12.44
数据加载中...
总览
公司
新闻资讯
公告
概念
医药生物股
+1.74%
资金流向
资金流入:
资金流出:
实时
日
周
月
季度
年
新闻资讯
BUZZ-雷特(Rett)药物在欧洲市场受挫,杰富瑞下调澳大利亚 Neuren 公司的目标价和盈利预期
路透中文
·
02/06
Neuren制药公司就缺氧缺血性脑病新药临床试验申请计划获监管反馈
美股速递
·
02/04
BUZZ-澳大利亚 Neuren 公司雷特综合症治疗药物申请因欧洲监管机构受挫而下挫
路透中文
·
02/03
Neuren Pharmaceuticals获欧洲药品管理局人用药品委员会通知
美股速递
·
02/03
{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"老虎国际,美股交易,港股交易,交易美股,股票信息,股价,美股行情,美股打新,港股打新,IPO打新,购买美股,全球投资","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/NEU.AU"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"NEU.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"NEU.AU\",,,,,undefined,":{"symbol":"NEU.AU","market":"AU","secType":"STK","nameCN":"NEUREN PHARMACEUTICALS LTD","latestPrice":13.51,"timestamp":1770700320000,"preClose":13.31,"halted":0,"volume":601984,"delay":0,"changeRate":0.015026296018031501,"nameEN":"NEUREN PHARMACEUTICALS LTD","floatShares":108394581,"shares":126639526,"eps":1.147709,"marketStatus":"已收盘","change":0.2,"latestTime":"02-10 16:12:00 AEDT","open":13.32,"high":13.56,"low":13.04,"amount":8056584,"amplitude":0.039068,"askPrice":13.88,"askSize":385,"bidPrice":13.51,"bidSize":122,"shortable":3,"etf":0,"ttmEps":1.147709,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":0,"beginTime":1770764400000},"marketStatusCode":5,"adr":0,"exchange":"ASX","adjPreClose":13.31,"openAndCloseTimeList":[[1770678000000,1770699600000]],"volumeRatio":0.686544,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"NEU.AU\",,,,,undefined,":{"symbol":"NEU.AU","floatShares":108394581,"roa":"41.13%","roe":"54.96%","lyrEps":1.086099,"volumeRatio":0.686544,"shares":126639526,"dividePrice":0,"high":13.56,"amplitude":0.039068,"preClose":13.31,"low":13.04,"week52Low":8.61,"pbRate":"5.29","psRate":"7.82","week52High":22.985,"institutionHeld":0,"latestPrice":13.51,"committee":-0.518738,"eps":1.147709,"divideRate":0,"volume":601984,"delay":0,"ttmEps":1.147709,"open":13.32,"prevYearClose":18.61,"prevWeekClose":12.52,"prevMonthClose":16.69,"prevQuarterClose":18.61,"fiveDayClose":14.63,"twentyDayClose":19.32,"sixtyDayClose":18.64},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NEU.AU\",params:#limit:5,,,undefined,":[{"date":"2025-02-28","symbol":"NEU.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1740697200000,"name":null,"time":"","dateTimestamp":1740661200000,"actualEps":null},{"market":"AU","date":"2024-02-29","symbol":"NEU.AU","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1709125200000,"reportTimeType":"","actualEps":null},{"date":"2023-08-28","symbol":"NEU.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1693180800000,"name":null,"time":"","dateTimestamp":1693144800000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NEU.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NEU.AU\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2609958989","title":"BUZZ-雷特(Rett)药物在欧洲市场受挫,杰富瑞下调澳大利亚 Neuren 公司的目标价和盈利预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2609958989","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609958989?lang=zh_cn&edition=fundamental","pubTime":"2026-02-06 04:06","pubTimestamp":1770321964,"startTime":"0","endTime":"0","summary":"由于自动化翻译可能有误,或未能包含所需语境,路透不保证自动化翻译文本的准确性,仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失,路透不承担任何责任。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260205:nL4T3Z12IJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2065170008.USD","LU2065171311.SGD","NEU.AU","BK7508","ACAD","BK4139","LU2065169927.USD","LU2065171402.SGD","BK7096"],"gpt_icon":0},{"id":"1152637192","title":"Neuren制药公司就缺氧缺血性脑病新药临床试验申请计划获监管反馈","url":"https://stock-news.laohu8.com/highlight/detail?id=1152637192","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1152637192?lang=zh_cn&edition=fundamental","pubTime":"2026-02-04 14:11","pubTimestamp":1770185472,"startTime":"0","endTime":"0","summary":"Neuren Pharmaceuticals Ltd(NEU.AU)近日宣布,已收到关于其针对缺氧缺血性脑病(HIE)的新药临床试验(IND)申请计划的相关反馈意见。\n该反馈涉及公司计划向监管机构提交的IND申请的具体方案,标志着其在HIE治疗药物研发进程中迈出重要一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7096","NEU.AU"],"gpt_icon":0},{"id":"2608196148","title":"BUZZ-澳大利亚 Neuren 公司雷特综合症治疗药物申请因欧洲监管机构受挫而下挫","url":"https://stock-news.laohu8.com/highlight/detail?id=2608196148","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608196148?lang=zh_cn&edition=fundamental","pubTime":"2026-02-03 08:02","pubTimestamp":1770076936,"startTime":"0","endTime":"0","summary":"2月3日 - ** 生物制药公司Neuren Pharmaceuticals NEU.AX股价暴跌22.1%至12.660澳元,创下2018年8月初以来最大盘中跌幅。(为便利非英文母语者,路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误,或未能包含所需语境,路透不保证自动化翻译文本的准确性,仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失,路透不承担任何责任。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260203:nL4S3YZ00C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","LU2065170008.USD","NEU.AU","BK7096","LU2065171402.SGD","BK4139","LU2065169927.USD","LU2065171311.SGD","ACAD"],"gpt_icon":0},{"id":"1122324471","title":"Neuren Pharmaceuticals获欧洲药品管理局人用药品委员会通知","url":"https://stock-news.laohu8.com/highlight/detail?id=1122324471","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1122324471?lang=zh_cn&edition=fundamental","pubTime":"2026-02-03 06:42","pubTimestamp":1770072164,"startTime":"0","endTime":"0","summary":"Neuren Pharmaceuticals Ltd (NEU.AU) 已收到欧洲药品管理局人用药品委员会(CHMP)的正式通知。该通知涉及公司相关药品的审评进展,标志着其在欧洲监管审批流程中的重要节点。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","NEU.AU","BK7508"],"gpt_icon":0}],"pageSize":4,"totalPage":2,"pageCount":1,"totalSize":6,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/NEU.AU\",params:#limit:6,delay:true,,,undefined,":[{"market":"AU","name":"医药生物股","bkCode":"BK7508","id":"package_au_concept_yyswg","changeRate":0.017447}]}}